公司新闻2023-03-10
博腾股份首次获标普全球ESG评级覆盖
2月28日,标普全球企业可持续发展评估(S&P Global Corporate Sustainability Assessment)公布新一轮环境、社会及公司治理(ESG)评分结果,重庆博腾制药科技股份有限公司(股票简称:博腾股份,股票代码:300363)获得首次覆盖,且评分超过全球行业平均分位。此前,公司已获得深交所国证ESG AA评级、中财绿金院A+评级、MSCI ESG BBB评级等多个国内外ESG主流评级机构覆盖,并获选2022年度中国上市公司ESG百家榜单、2022年中国医药上市公司最具ESG投资价值TOP10等奖项,ESG实践持续获得认可。
On February 28th, S&P Global released a new wave of S&P Global ESG Scores resulting from the annual Corporate Sustainability Assessment (CSA). Porton Pharma Solutions Ltd. (SZ300363) is covered for the first time and scored 29 out of 100, which is above the industry average. As of February 17th, Porton performed in the top quartile in the pharmaceuticals industry in the S&P Global Corporate Sustainability Assessment.
标普全球企业可持续发展评估于1999年发起,是全球规模最大的企业可持续发展实践年度评估之一,评估通过对企业的公司治理、环境保护、社会责任等多维度指标进行分析,将每家企业的平均1000个数据点进行分析并转化为ESG评分,全面反映企业的ESG管理和信息披露水平。
Porton has attached great importance to the sustainable development and integrated ESG concept into daily operation. We focus on the demands of customers, employees, shareholders, suppliers, environment, communities and other stakeholders and actively respond to them by multiple practices, such as improving corporate governance, compliance operation, reliable products and services, diverse and inclusive work environment, sustainable supply chain and green development. Meanwhile, Porton conscientiously practices corporate social responsibility and actively participates in social welfare undertakings.
博腾股份始终坚持可持续发展理念,关注客户、员工、股东、供应商、环境、社区等各利益相关方的需求,并通过完善治理、合规运营、可靠的产品和服务、多元包容的工作环境、可持续供应链、绿色发展等多维度实践,积极回应利益相关方,将ESG理念融入公司经营的各个环节。另外,公司认真践行企业社会责任,积极投身社会公益事业。2022年,公司通过物资捐助及参与志愿者活动积极支持抗疫行动,捐赠物资驰援重庆山火救援,启动公益品牌“腾益计划We Care”,持续落地社会公益活动。未来,我们将继续践行ESG发展理念,致力高质量的可持续发展,为利益相关方创造价值。
Previously, Porton has been covered by several global ESG rating agencies. We’ve got AA in CNI ESG ratings, A+ in IIGF ESG ratings and BBB in MSCI ESG ratings in 2022. Porton has also won some ESG awards such as 2022 TOP 100 ESG Chinese Listed Companies and 2022 TOP 10 Chinese Pharmaceutical Listed Companies with The Most ESG Investment Value. Porton’s ESG practice has been continuously recognized.
相关新闻
了解更多公司新闻2024-10-31
里程碑 | 博腾股份奉贤工厂产能升级,New Modality领域服务能力全面提升
近期,博腾股份在其位于上海奉贤的生产基地实现了重要产能突破,进一步提升了其在多肽与寡核苷酸药物等New Modality领域的产能和技术实力。这一升级是博腾致力于成为全球领先CDMO公司的重要一步。
公司新闻2024-10-24
合作共赢 | 博腾股份与益诺思达成战略合作
2024年10月24日,重庆博腾制药科技股份有限公司(以下简称“博腾股份” “博腾”)与上海益诺思生物技术股份有限公司(以下简称“益诺思”)于上海宣布达成战略合作。博腾股份董事长兼总经理居年丰先生,益诺思总裁常艳博士,博腾股份副总经理皮薇女士,博腾股份营销中心副总经理孟凡女士,益诺思非临床药效学评价技术创新分中心高级总监房鑫博士,益诺思市场部副总监赵洁女士等出席签约仪式。